This study will be conducted on 7 cohorts of cancer patients and 1 cohort of non-cancer subjects (age and gender matched) with a sample size of 30 patients in each cohort:~All enrolled patients will be asked to provide blood samples (2 x 10cc Heparin Tubes) at the following time points:~Baseline: before the administration of the first dose of the SARS-CoV-2 vaccine (within 4 weeks).~Before the second dose of the SARS-CoV-2 vaccine (within 7 days).~Follow-up: after 3, 6, 9 and 12 months after the second dose of the SARS-CoV-2 vaccine. A +/- 14 days window is allowed at each follow-up time point.
This is a single centre prospective observational study to assess the immune response to SARS-CoV-2 vaccines in cancer patients receiving active treatment or in follow-up at the IOSI and in non-cancer patients (age and gender matched).